Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Daiichi Sankyo Co. v. Matrix Laboratories, Ltd. (Fed. Cir. 2010)

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Donald Zuhn -- In Daiichi Sankyo Co. v. Matrix Laboratories, Ltd., decided last Thursday, the Federal Circuit affirmed a determination by the District Court for the District of New Jersey that Matrix Laboratories, Ltd., Mylan Inc., Mylan Laboratories, Inc., and Mylan Pharmaceuticals, Inc. ("Mylan") failed to establish a prima facie case of obviousness with respect to claim 13 of U.S. Patent No. 5,616,599. Daiichi Sankyo Company, Ltd. and Daiichi Sankyo, Inc. own the '599 patent, which relates to 1-biphenylmethylimidazole compounds and their use as angiotensin receptor blockers (ARBs) for the treatment of high blood pressure. Claim 13 of the...

Full post as published by Patent Docs on September 14, 2010 (boomark / email).